ESTRO 2024 - Abstract Book

S1753

Clinical - Lung

ESTRO 2024

3. Nguyen, K.S., S. Kobayashi, and D.B. Costa, Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer, 2009. 10(4): p. 281-9.

4. Camidge, D.R., W. Pao, and L.V. Sequist, Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol, 2014. 11(8): p. 473-81.

5.

Pisano, C., et al., Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK

Rearrangements. Cancers, 2022. 14(3): p. 718.

6.

Weiss, J., et al., Phase II study of stereotactic radiosurgery for the treatment of patients with

oligoprogression on erlotinib. Cancer Treat Res Commun, 2019. 19: p. 100126.

7. Weickhardt, A.J., et al., Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non – Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2012. 7(12): p. 1807-1814. 8. Tsai, C.J., et al., Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression ― Interim Analysis of the First Randomized Study of Stereotactic Body Radiotherapy in Patients With Oligoprogressive Metastatic Cancers of the Lung and Breast. International Journal of Radiation Oncology*Biology*Physics, 2021. 111(5): p. 1325-1326. 9. McDonald, F., et al., EP08.03-005 HALT - Targeted Therapy with or without Dose-Intensified Radiotherapy in Oligo-Progressive Disease in Oncogene Addicted Lung Tumours. Journal of Thoracic Oncology, 2022. 17(9, Supplement): p. S492.

2615

Digital Poster

Cardiac Survival Limiting Toxicity in Locally Advance Lung Cancer Patients Treated with RT.

Alessandro Cicchetti 1 , Alessandra Catalano 2 , Eliana Gioscio 2 , Albina Allajbej 3 , Anna Cavallo 4 , Silvia Meroni 4 , Chiara Veronese 5 , Paola Vallerio 5 , Claudia Sangalli 3 1 Fondazione RICCS Istituto Nazionale dei Tumori di Milano, Data Science Unit, Milan, Italy. 2 Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Data Science Unit, Milan, Italy. 3 Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Radiation Oncology, Milan, Italy. 4 Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Medical Physics, Milan, Italy. 5 Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Cardiopulmonary Unit, Milan, Italy

Purpose/Objective:

The heart is believed to be the most critical normal structure responsible for these competing events, and a better knowledge of its substructures' tolerance to RT is essential. However, studies defining the biology that drives the dose-response relationships have been limited, and the results are controversial [1], even when considering the mean dose to the heart (MHD). A reasonable option is a needful shift to the heart substructures (HSs) to understand better the causality of major adverse cardiac events (MACEs) after RT.